Clindamycin Phosphate and Benzoyl Peroxide NDC 70710-1445

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1445Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1445Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70710-1445-4	70710144504	1 TUBE in 1 CARTON (70710-1445-4) / 45 g in 1 TUBEMarketed from Mar 7, 2019

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Clindamycin Phosphate and Benzoyl Peroxide
Generic name (nonproprietary): clindamycin phosphate and benzoyl peroxide
Active ingredients: Clindamycin phosphate — 10 mg/gBenzoyl peroxide — 50 mg/g
Dosage form: Gel
Route: Topical
Labeler: Zydus Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210794
Marketing start: Mar 7, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Sebaceous Gland Activity (Physiologic effect)Lincosamides (Chemical structure)Neuromuscular Blockade (Physiologic effect)
Identifiers: Product ID 70710-1445_96b1eb6c-b99b-4509-a8eb-424123aead6aSPL ID 96b1eb6c-b99b-4509-a8eb-424123aead6aSPL set ID 83d52507-99a1-4461-b067-5ec01dc6c5d3RxCUI 1540241UNII EH6D7113I8, W9WZN9A0GM
Pharmacologic class: Lincosamide Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470710144504 followed by a unit qualifier and the quantity

Package 70710-1445-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 5, 2022.

Indications (excerpt from the label)

Clindamycin phosphate and benzoyl peroxide gel is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of inflammatory acne vulgaris. ( 1.1 ) Limitation of Use: Clindamycin phosphate and benzoyl peroxide gel has not been demonstrated to have any additional benefit when compared with benzoyl peroxide alone in the same vehicle when used for the treatment of non-inflammatory acne. ( 1.2 ) 1.1 Indication Clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% is indicated for the topical treatment of inflammatory acne vulgaris in patients 12 years and older. 1.2 Limitations of Use Clindamycin phosphate and benzoyl peroxide …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210794

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210794
Product	Strength	Form · route	Labeler	Product NDC
Clindamycin Phosphate and Benzoyl Peroxide	Clindamycin phosphate 10 mg/g; Benzoyl peroxide 50 mg/g	GelTopical	Zydus Lifesciences Limited	70771-1450